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Abstract
Background: Patient and public involvement for co-creation is increasingly recognized as a valuable strategy to
develop healthcare research targeting patients’ real needs. However, its practical implementation is not as advanced
and unanimously accepted as it could be, due to cultural differences and complexities of managing healthcare
programs and clinical studies, especially in the rare disease field.
Main body: The European Neuromuscular Centre, a European foundation of patient organizations, involved its key
stakeholders in a special workshop to investigate the position of the neuromuscular patient community with respect to
healthcare and medical research to identify and address gaps and bottlenecks. The workshop took place in Milan (Italy)
on January 19–20, 2018, involving 45 participants who were mainly representatives of the patient community, but also
included experts from clinical centers, industry and regulatory bodies. In order to provide practical examples and
constructive suggestions, specific topics were identified upfront. The first set of issues concerned the quality of life at
specific phases of a patient’s life, such as at the time of diagnosis or during pediatric to adult transition, and patient
involvement in medical research on activities in daily living including patient reported outcome measures. The second
set of issues concerned the involvement of patients in the management of clinical research tools, such as registries and
biobanks, and their participation in study design or marketing authorization processes. Introductory presentations were
followed by parallel working group sessions, to gain constructive contributions from all participants. The concept of
shared decision making was used to ensure, in discussions, a partnership-based identification of the wishes and needs
of all stakeholders involved, and the “ladder of participation” tool served as a model to evaluate the actual and the
desired level of patients’ involvement in all topics addressed. A general consensus on the outcome of the meeting was
collected during the final plenary session.
This paper reports the outcome of the workshop and the specific suggestions derived from the analysis of the first set
of topics, related to quality of life. The outcomes of the second set of topics are reported elsewhere and are only briefly
summarized herein for the sake of completeness.
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Conclusions: The neuromuscular community proved to be very active and engaged at different levels in the healthcare
initiatives of interest. The workshop participants critically discussed several topics, providing practical examples where
different stakeholders could play a role in making a change and bridging gaps. Overall, they indicated the need for
education of all stakeholders for better communication, where everyone should become an ambassador to promote real
change. Support should also come from institutions and healthcare bodies both at structural and economic level.
Keywords: Healthcare, Patient engagement, Patient involvement, Neuromuscular diseases, Co-creation
Background
The European policy concepts of “open science”, “co-cre-
ation”, and “responsible research and innovation” define
new approaches in the processes of strategic research &
development and decision making in which all involved
stakeholders, including citizens, contribute to reach conclu-
sions that apply to a broader range of expectations [1]. In
practice, it means it is pivotal for science to reach out to
stakeholders and engage with them in order to speed up
innovation and knowledge to increase the wellbeing of citi-
zens and patients. Co-creation means collaborative gener-
ation of knowledge, which in health research relates to the
active involvement of patients in experience-based study
design of patient-centered health services, research out-
comes and clinical investigations [2–4]. The need to engage
patients has been solicited at several levels, from setting
political and research agendas to building networks to
share their experiential knowledge and perspective with ac-
ademics, clinicians and industry [5–7]. Despite the fact that
much has been conceptualized about patient participation
(and there is growing evidence of its implementation),
much still needs to be done to consolidate practice, explore
models of participation and provide clear evidence of its
benefits and value [4, 8]. For patients and Patient Organiza-
tions (POs) this is a time to discuss if and when they want
to participate and how they can contribute to a co-creation
process for better-tailored medical interventions.
In the neuromuscular disease (NMD) field, these ap-
proaches have long been embraced and supported by the
European Neuromuscular Centre (ENMC) [9], a European
foundation of empowered NMD POs, whose mission is to
promote research and improve quality of life (QoL) of
people with NMD. Through the sponsorship of highly fo-
cused workshops, the ENMC encourages and facilitates
communication and collaboration in the NMD field by pro-
moting interaction among experts (researchers, clinicians,
other healthcare professionals, regulators, etc.), including
patient representatives [10, 11]. In 2018, the ENMC cele-
brated its 25th anniversary of activity by engaging its main
stakeholders in a special workshop to understand how the
NMD patient community impacts upon the healthcare and
science co-creation scenario. The workshop took place in
Milan (Italy) on January 19–20, 2018 and involved 45
participants from 15 countries, including representatives of
POs, clinical researchers, industry and regulatory
authorities.
The “Shared Decision Making” (SDM) concept [12–
14] and the “participation ladder” model [15, 16] were
used as working tools to set the stage for discussion
about the position of patients affected by NMDs with re-
spect to their active participation in healthcare and re-
search initiatives.
Why promote SDM?
SDM has been defined as: “an approach where clinicians
and patients share the best available evidence when
faced with the task of making decisions, and where pa-
tients are supported to consider options, to achieve in-
formed preferences” [13].
In practice SDM implies effective communication be-
tween health professionals and their patients about the
options of prevention, screening, diagnostic tests and
available treatments for their disease, including the
choice of not intervening. Through a structured dia-
logue, medical doctors promote patients’ knowledge of
the existing opportunities and a correct perception of
benefits versus risks. Moreover, they work towards un-
derstanding values and preferences of patients and their
families with respect to the available options, taking into
consideration barriers and facilitators that influence their
practical implementation. Joint decisions derived from
better-informed patients lead to reassurance and confi-
dence regarding the choices made and makes patients
more confident about their treatment options, ultimately
leading to better compliance. Saving money is not a pri-
mary objective, but this can nonetheless be one of its
consequences. SDM is particularly relevant when uncer-
tainty is high, i.e. when all the available options have
drawbacks or when no evidence is available of what the
best option might be [13, 14, 17].
The ladder of participation – real involvement or
tokenism?
The concept of a ladder of participation model goes
back to 1969, when Sherry Arnstein proposed it to dis-
cuss the extent of citizens’ power in determining the end
product [15]. She envisaged three broad levels, ranging
from non-participation, tokenism, to real power and full
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control, with different degrees, or rungs, for each of
these categories. This concept has been used to investigate
the level of engagement and type of role of patients and cit-
izens play in healthcare decision making [18, 19]. Moving
beyond the classical, normative structure suggested by Arn-
stein, Tritter and McCallum [16] argued that when health
issues are concerned, the ultimate goal of patients is not
necessarily to reach full power and control, as it is “the
process rather than the outcome that has the greatest po-
tential for changing organizational culture”. In other words,
they suggested that all the different levels of participation in
the higher part of the ladder are relevant. In fact, gaining
full power of the governance aspect is not always the target,
since decision making in health research may derive from
the harmonization of different viewpoints from different
stakeholders. The role of patients’ may vary depending on
the context, their competences and the resources available.
Studies from Abma and collaborators have shown the var-
iety of roles and conditions under which patients or their
representatives have been able to effectively contribute to
research practices [20]. It must be born in mind that part-
nering with patients and families for collaborative projects
should be seen as a means to improve healthcare, and par-
ticipation is not the ultimate goal per se [4].
Aligned with these views, in this workshop we wanted
to investigate the experience of the NMD community re-
garding patient – clinician partnerships for both health-
care delivery and research. In particular, we wanted to
understand where and to what extent patients can play
an active role in these processes, and also to understand
what they hope to gain through their involvement.
Therefore, we adopted the model as in de Wit [19],
which considers different levels of involvement.
The lowest, non-participation level is limited to when the
information given to the patient by the professional is about
decisions that have already been made. The level of sym-
bolic consultation is reached when the patient’s advisory
role is requested only after or at the end of the decision
process, thereby limiting the possible influence of the pa-
tient on the process. At ‘the collaboration level’, patients
provide information on their condition and medical needs
and give advice to clinicians. This role as partners in the
process of production of knowledge and co-creation of new
health research models and tools involves, for instance, pro-
viding input about the development of new functional out-
come measures, or into studies targeting activities of daily
living, or on the design of technological devices. When the
‘control’ level is reached, patients take the initiative and
hold varying degrees of power depending upon their rela-
tive contribution and ownership of the process (Fig. 1).
The ENMC workshop
The SDM model and the participation ladder were used
as tools to operationalize participation of the different
stakeholders attending the meeting. The main objectives
of the workshop were: i) to analyze the current state of
play of patient involvement in the NMD field with regard
to the topics selected; ii) to identify critical issues and
types of intervention; and iii) to identify priority issues
from all stakeholders that need to be addressed in practice
and how this should be achieved.
The discussion focused upon 6 specific topics related to
patient participation in healthcare delivery: topic 1; psy-
chosocial support for families undergoing medical diagno-
sis and/or prenatal and predictive genetic testing; topic 2;
transition from childhood to adulthood; and topic 3; the
impact of patient participation in all aspects of medical re-
search (such as QoL, patient-reported outcome measures
(PROMs), other outcomes and interventions); topic 4;
registries and biobanks; topic 5; design and implementa-
tion of clinical trials; and topic 6; interaction with regula-
tory authorities. Successful examples including individual
patient reports were illustrated during plenary sessions,
Fig. 1 Levels of patient involvement along the participation ladder
(A. Ambrosini; modified from [19])
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followed by structured group feedback, which engaged all
participants to assess critical issues, share their experience,
and provide practical inputs.
The content of this paper reflects the outcome of work-
shop topics 1–3 and, in particular, it focuses on the QoL-
related healthcare session (topics 1 to 3). This includes the
specific needs identified and priority areas for implementa-
tion including: where and how patient involvement could
make a difference and how this might best be achieved. The
outcomes of topics 4–6 are reported elsewhere and for this
reason will only be briefly mentioned [21].
Methods
Contents and structure of the workshop
The content of this workshop was set up by the Executive
Committee of the ENMC together with its Research Dir-
ector. The identification of the two working models, SDM
and participation ladder, was based on extensive preliminary
review of the literature regarding patient engagement. The
choice of the six topics that were investigated derived from
ENMC members’ knowledge of the field, strategic analysis
of the outcomes of ENMC sponsored workshops, evaluation
of the broad international NMD network activities, and con-
sultation with the ENMC Research Committee members.
The workshop structure consisted of plenary lectures,
aimed at setting the groundwork for the discussion,
followed by parallel working groups that involved all par-
ticipants in the discussion on the specific topics (Fig. 2).
In order to provide the audience with the instruments
to be used during the discussion, Guus Schrijvers intro-
duced the SDM concept and Ingeborg Meijer illustrated
the ladder of participation model. She also provided the
participants with operational instructions about the
workshop.
Session 1, “SDM in Quality of Life and psychosocial
support”, consisted of three plenary presentations focused
on topics 1 (genetic screening and diagnosis), 2 (transition
from childhood to adulthood), and 3 (impact of medical
research in QoL, aimed at providing: evidence-based ex-
amples of effectiveness of patient involvement in health-
care, practical elements and ‘real life’ experience of the
benefits of being engaged.
Session 2, “SDM in clinical research and trial design”
was introduced by the ENMC Research Director, George
Padberg, who adopted the principles of SDM and patient
involvement in research to investigate their possible
roles in the critical scenario represented by the imple-
mentation of personalized medicine in the NMD field,
and its consequences for the future. Three plenary
presentations followed, targeting topics 4 (registries and
biobanks), 5 (clinical trials), and 6 (regulatory and con-
senting processes).
After each session of talks, all participants were divided
into three parallel discussion groups, each addressing one
of the topics.
During Session 3, the outcomes of the six working
groups were presented in a plenary session and discussed
with the whole workshop, and a consensus on the key
messages was reached among all participants.
In order to make the results of the workshop easier to
follow, a brief highlight of each specific topic of Session
1 is reported, followed by the outcome of the respective
working group.
Terminology
The terminology used in this paper refers to the Na-
tional Institute for Health Research (UK) definitions
[22] namely:
Fig. 2 Structure of the workshop’s working groups
Ambrosini et al. Orphanet Journal of Rare Diseases          (2019) 14:126 Page 4 of 12
a) patient and public involvement is the development
of partnerships between patients, carers or other
members of public and researchers. Such partnerships
are made in order to influence what research is done,
how, and what happens to the results;
b) patient and public engagement is the sharing of
information and knowledge about research by
professionals, such as during open days, science
festivals or through newspapers or other media;
c) patient and public participation is the recruitment
of patients or others to take part in clinical trials or
other research studies.
This terminology is adopted irrespective of the partici-
pation ladder connotations and is meant to unambigu-
ously define the type of contribution by patients in their
partnership with professionals for medical research.
Results
Session 1 - SDM in quality of life in NMDs: psychosocial
support
Health-related QoL is a broad concept that defines the
perceived quality of an individual’s daily life from differ-
ent perspectives, which refer to physical, emotional and
social aspects, according to the original World Health
Organization definition [23]. Specific instruments have
been developed to assess patients’ well-being or lack
thereof, such as PROMs and QoL surveys. In general,
these tools are meant to capture directly from patients
the impact on their daily life of the disease and, where
applicable, of a treatment or a technological device. The
definition and implementation of these instruments is
based on the fruitful collaboration among various stake-
holders (patients, clinicians, biomedical engineers, etc.).
At the workshop, participants discussed how to promote
better QoL in people living with a NMD condition,
examining ethical and psychological issues related to sig-
nificant phases in their lives, from the diagnostic process
to the transition from childhood to adolescence and
adulthood, how to contribute to the development of
PROMs and clinical studies targeting daily life issues.
Emphasis was put on the contribution of patients in de-
fining research priorities, as well as any related chal-
lenges and how they might be overcome.
Topic 1: SDM in helping patients and families go through
genetic testing (prenatal and predictive) and/or diagnosis
Introductory talk 1 – knowledge is power Topic 1
was introduced by Aad Tibben. He presented a summary
of the positive experience of the European Huntington’s
disease (HD) network (EHDN) [24] to highlight the im-
portance of the synergy among people affected by a rare
disease and their relatives, clinicians and researchers and
the need for them to work together to advance research
and improve quality of care. In particular, he addressed
the psychological needs related to diagnosis and/or pre-
dictive testing for HD, two clinical services with different
purposes that bring very different ethical issues. Aad
Tibben demonstrated how the excellent interaction that
occurs within the EHDN allowed them to develop im-
portant recommendations for genetic counselling within
families [25, 26]. While presenting data on this experi-
ence, Tibben discussed several aspects related to the psy-
chological burden of affected people and their relatives
that may also apply to other serious rare genetic dis-
eases, including many NMDs, and indicated how good
practice of SDM is important to give patients and their
families the skills to deal with these difficult issues.
He cited the philosophical motto “Knowledge is power”,
adapting it to the current field of genetics, which has seen
tremendous technological advances in recent years. Easy
access to the world-wide web and social media has en-
abled people to gain detailed information about their spe-
cific condition when available. Thus, mutual dependency
of all stakeholders and SDM are essential to make this in-
formation powerful and fruitful. Diagnostic or predictive
testing together with good SDM allow for the promotion
of patient autonomy, individually tailored decision-
making, environmental mastery, and ultimately improve-
ment of QoL. Tibben pointed out that this is the future of
medicine and it requires adaptation of all stakeholders in-
volved, to better define concepts on SDM, improvement
of stakeholders’ discourse, definition of responsibilities
and boundaries, formalization of arrangements and struc-
tures, and legal and ethical considerations.
Panel discussion This working group acknowledged
that, indeed, several of the issues and hurdles described
by Aad Tibben are also common experience within the
NMD community, including genetic diagnosis of an af-
fected person and predictive testing in siblings or other
relatives. Many NMDs are congenital in onset and affect
primarily children and the group discussed if or when it
would be the best time to test a younger sibling who
might be either unaffected or pre-symptomatic when no
therapeutic options are available. This scenario is start-
ing to change for Duchenne muscular dystrophy (DMD)
and spinal muscular atrophy (SMA) where therapeutic
options are now available [27–29]. These developments
call for a change in medical practice to identify pre-
symptomatic children and, in particular, to initiate pro-
grams for neonatal screening. Indeed new care guide-
lines developed by specialists with the PO support have
been released [30–33]. The POs emphasized the import-
ance of families knowing their specific DNA mutation
and for them to receive guidance on the best medical
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options for their QoL through a well-structured SDM
process.
From these observations, the panel concluded there is
a strong need to create awareness and effective commu-
nication between doctors and patients/parents, and to
identify specific roles and competencies on both sides
(Table 1A).
As a starting point, the group also identified specific
action points including:
– Setting up a diagnosis/screening group involving
experts and the disease-specific POs to address op-
portunities, hurdles and ethical issues related to the
different options and time points of genetic testing
and prenatal/neonatal screening programs.
– Develop a proactive approach to upcoming
therapeutic options, and take actions according to
the opportunities ahead.
– Promote awareness about the requisites for
predictive testing and launch surveys in the patient
population to investigate best practices, identify “do’s
and don’ts” and specific wishes of disease groups.
– Proactively seek applications to the ENMC for
workshops around these suggestions.
The panel argued that mutual support between pa-
tients/families and clinicians is essential to succeed in
improving genetic testing procedures and counselling. In
particular, POs may contribute to this process by creat-
ing awareness and establishing support groups, while
doctors can support a peer-to-peer mentoring (i.e. to fa-
cilitate discussion on the impact of decisions that may
differentially affect QoL). POs recognized their responsi-
bility in promoting change and were persuaded that if
patients change, doctors will follow.
Topic 2: SDM in transition from child to adolescent, to adult
patient
Introductory talk – growing in SDM Ros Quinlivan
discussed how to prepare young people for SDM,
through a process that needs change from a paternalistic
approach for young children to a shared approach for
adolescents and finally to informed SDM for older teen-
agers. She reported the experience of the MDStarNet
with boys and young men with DMD [34]. The new
population of young adults with DMD is healthier than
before and thus there are new issues and expectations
arising. Young adults with DMD are more independent
and do not want to be considered different from their
peers. However, they may not always necessarily under-
stand their condition and the importance of health
screening and in some cases may be less aware that they
have a life-limiting condition. This can result in a high
rate of non-attendance for routine follow-up appoint-
ments, sleep studies and cardiac examinations at the
care centers. In addition, young patients may be unaware
that they can make choices regarding future healthcare
planning [35].
Teenage healthcare behaviours impact on outcomes
and, in general, a greater rate of risky behaviours are re-
ported in young people with chronic conditions [36–39].
Quinlivan examined the types of support young people
need to make decisions. In her experience, these include:
i) information: young people can make informed choices
only by understanding their condition and the options
available to them; ii) autonomy, which needs to be guar-
anteed to involve them in SDM; iii) coaching and men-
torship; iv) support - teenagers need support and
guidance from parents, professionals and peers, other-
wise they will be anxious and afraid to be involved in
SDM.
She illustrated how, with support from the PO Muscu-
lar Dystrophy UK and a clinical psychologist, patients at-
tending her service at The National hospital for
Neurology and Neurosurgery were given structured peer
support to grow their self-confidence in taking over their
own decision making. This included: the development of
a hospital-wide young persons’ (YP) steering committee
to improve services, with representation from young
people on the committee, a YP peer support group facili-
tated by a clinical psychologist; information specific for
YP, and an information day on practical issues such as
applying for university; getting a driving licence and liv-
ing independently and working with a disability [40].
Transition should start early, from about 12 years of age
with a key worker and clear goal setting together with
aspirations for the future. They need knowledge so that
they can learn how to manage their own medical needs,
such as being able to recall their medication and doses
or understanding what each medication is for. In es-
sence, to prepare young people with NMD for SDM,
they need to understand their condition, they should be
progressively involved in decision making initially with
their parents and, as they become more confident, they
should be involved in SDM with or without support
from their family. POs can play a major role in facilitat-
ing this process, for instance by: i) creating support
groups together with professional experts, as in the UK
example reported above; ii) promoting the development
of young patient advisory groups, and iii) structuring fo-
cused initiatives with the families as part of their main
organization’s activities.
Panel discussion This working group focused the dis-
cussion on the transition from childhood to adolescence
of young people with DMD, as a paradigm for the topic.
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The group acknowledged that enabling children with a
chronic condition to acquire proper skills in decision mak-
ing is indeed relevant for them to better handle their life
and become empowered adults. However, this process re-
quires actions at several levels, which involve physicians,
healthcare practitioners, parents, and caregivers. Four
areas of priority where formulated, namely: 1. Coaching
behavioral change; 2. Increase knowledge to enable SDM;
3. Increase role of society to enable participation; 4. Pro-
mote changes in healthcare services to meet the complex
health needs of this population of YP (Table 1B).
In particular, coaching and support of patients and their
parents and caregivers should be promoted, in order to
grow self-esteem and confidence in young people and to
help them understand the value of behavioral changes and
adopt healthy and constructive attitudes into adulthood.
SDM should facilitate the discussion on diagnosis, treat-
ment options, sexuality, family planning and life choices,
with psychological support offered at every stage.
Relevant material should be produced to address edu-
cational needs, involving POs and patients themselves in
this co-creation process that generates ambassadors for
spreading a cultural change. Financial support for transi-
tion programmes and patient advocacy groups should be
made available by national or international institutions.
It was also suggested that a specific workshop could
help to set the stage for these changes and delve deeper
into the conceptual changes required to enable a child
with an NMD to acquire the skills for SDM.
Topic 3: SDM in research that has major impact on daily
life
Introductory talk – health care research requires co-
creation Based on his personal experience as a patient
representative in the international research community
“Outcome Measures in Rheumatology” (OMERACT),
Maarten de Wit focused on the role of patient research
partners in different phases of health research. A patient
research partner is defined as a person with a relevant
condition who provides a patient perspective in the re-
search team as an equal collaborator at all stages of the
project. As a first example, effective methods for involv-
ing patient research partners in research agenda setting
were presented. In the UK the James Lind Alliance has
supported many POs to prioritize research topics from
the perspective of patients [41]. In The Netherlands the
Dialogue model was developed as a step-wise approach
to elicit research priorities of different stakeholders, and
achieve consensus through heterogeneous focus groups
that ensure that the voice of patients is heard [42].
A second example followed the strategy of engaging
patients as research partners in the development of a
PROM for Psoriatic Arthritis [19]. This case study
demonstrated that listening to patients is critical to cap-
ture all that is important from the perspective of the tar-
get population to include in a new QoL questionnaire. It
also showed that having patient research partners on the
research team guaranteed that the voice of patients was
not lost during the final stages of validation. Finally, hav-
ing different forms of patient and public involvent (PPI)
at different stages of the development process, increased
the content validity of the final instrument.
Crucial factors of success for the involvement of patient
research partners are to: a) involve patient representatives as
collaborative partners from the outset; b) ensure the com-
mitment of the research centres’ leaders; c) prepare early
career researchers to interact in a constructive way with pa-
tients through creating the environment for an SDM culture
and by facilitating collaborative partnerships [43].
Panel discussion This group considered that, for effect-
ive involvement in developing research relevant to their
daily life, patients need to have a good understanding of
the real therapeutic opportunities and of how their input
could contribute to healthcare improvement. Physicians
need to understand the added value of spending more
time in SDM, which will be more likely to improve treat-
ment compliance and lead to constructive contributions
to research. It was argued that, in general, patients are
not fully involved in discussions relating to their condi-
tion and the benefits and risks of a certain treatment.
Therefore, they are not ‘trained’ to contribute to building
knowledge on what is relevant to them. Moreover, care
options relevant for a patient may not be taken into ac-
count because they are not part of the standardized
methods to measure efficacy and, as such, maybe un-
familiar to the physician. Examples were given of the
challenge of managing patients who are unable to speak,
where care options are more tailored to the caregiver
than to the patient’s real needs. These considerations
highlighted the key role of SDM and led to an examin-
ation of what the challenges are for a positive and fruit-
ful interaction between patients and physicians (Table
1C). It was acknowledged that fruitful communication
has to be based on the understanding of the information
gaps and on positive interpersonal contacts, centering
the discussion more “with the patient” than “against the
disease” [44]. All agreed that a cultural shift is needed
for all stakeholders. Actions that may be perceived as ex-
ploratory in the beginning could become, if successful,
accepted and even necessary once they demonstrate
their key value for the main objective. It was noted that
a methodological evaluation of a successful SDM could
be useful to show benefits and encourage its implemen-
tation in areas where it is not yet applied.
Finally, the group concentrated on how to address those
limitations that impair development of research that really
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targets patients’ daily needs. Special calls or programs for
clinical studies on QoL, with patient involvement on study
design and development of proper PROMs, and dedicated
funding for patients involvement in research approaches
can better address this need and also pave the way for
broad applicability [45–47].
Session B - patient involvement in clinical research, trial
design and regulatory affairs
A rapid increase in innovation and emergence of new
healthcare technologies has the potential to reshape patient
care and disease; i.e. gene therapy aims to repair the direct
cause of genetic disease, by introducing genetic material
into cells to compensate for mutated or faulty genes. Treat-
ing a range of diseases that until now have been incurable
may become possible in the near future. In this developing
scenario, patients not only want to be informed, but also
request to be active players to influence the developments
according to their main needs, by promoting services and
contributing to research as ‘expert patients’.
This session investigated opportunities and challenges
of direct involvement of patients in medical research
[21]. On the one hand it was considered how SDM
might be applied in research by facilitating patients’ un-
derstanding of the implications of their participation for
instance in a trial, thus favoring compliance. On the
other hand, this session delved more in the participation
ladder, by exploring where, in research, the active role
and engagement of patients can make the difference.
Several examples were described by participants that
have been involved in research-related activities at differ-
ent levels, being members of Eurordis [48], of the Euro-
pean Patients’ Academy on Therapeutic Innovation
(Eupati) [49] or the European Patient Forum [50]. They
reported their experience of participation at different re-
search steps, from early stages of translational research,
up to the actual delivery of a therapy in the ‘real world’,
as well illustrated in the literature [7, 51, 52]. There was
common agreement that patients and POs can greatly
contribute to implement services to research such as
registries and biobanks, by not only donating their data
or samples, but also playing a role in the governance
with high level of power and control. Regarding the de-
sign and implementation of clinical trials, patients
should be listened to and involved from the very begin-
ning, to provide input regarding the definition of trial
outcomes and the design of informed consents tailored
on their real need of information, and to contribute to dis-
seminate the information regarding the trial and its results
within their community [53, 54]. The relevance of includ-
ing disease-specific patients in regulatory agencies’ or eth-
ics’ boards was also recognized, with several examples
shared by participants that are already engaged in these
top level initiatives. Although it was acknowledged that
patient representatives are already taking up roles in deci-
sion boards, it was pointed out that in some cases their in-
clusion reflects more a tokenistic approach, without
having the proper patient expertise at the decision table
[21].
Conclusions
A growing body of literature emphasizes the relevance
of PPI as a means to promote clinical research of great
impact for patients’ real needs. The necessity to involve
patients in a co-creation process for collaborative gener-
ation of knowledge is also urged by international re-
search consortia [55], industry [7, 56] and regulatory
authorities (EMA) [51]. However, translating the overall
concept into practice still presents several challenges,
experienced both by clinical researches and PPI contrib-
utors [57]. With this workshop, the ENMC wanted to
discuss with its key stakeholders where the neuromuscu-
lar community stands in terms of PPI and co-creation in
research, where the major gaps are and what approaches
could be taken to address them.
Participants witnessed, through several positive exam-
ples, that a strong relationship and constructive inter-
action has been established among all stakeholders in
recent years, especially for those disease groups where
therapeutic options are now becoming available. Several
PO representatives participate in international patient
advisory groups, such as Eurordis, Eupati, or the Euro-
pean Patient Forum, indicating awareness of the value of
the contribution they can bring to the community.
The workshop also delved into the hurdles and bottle-
necks that still exist, addressing QoL of patients and fam-
ilies in specific phases of their life (i.e. at diagnosis or at
transition from child to adulthood), or how consolidated
is PPI in NMD clinical research. Table 1 of this report
summarizes what aspects the participants identified as pri-
orities regarding the topics discussed, and provides prac-
tical examples of how POs/patient representatives and
professionals could address them. It has to be noted that,
on the one hand this list is not meant to be exhaustive of
all the hurdles that people living with a NMD condition
may experience, while, on the other hand the proposed
examples can be generalized and represent a useful
approach to be taken also for other rare diseases.
Overall, the group identified three main levels for pro-
activity (Table 2).
First of all, fostering good communication is funda-
mental to understand one another and set the ground-
work for fruitful interactions (the SDM and participation
ladder concepts were used as working models). Proactiv-
ity, training, and good understanding of the required
level of PPI are other key elements and everyone who
embraces this view should act as ambassador to make
real change.
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With this workshop, the ENMC offered the plat-
form to discuss the level of PPI for patients with
NMDs and with this report it creates a tool for all
stakeholders to help implement the cultural, educa-
tional and structural changes at the local level and
expand the group of engaged patients. PO representa-
tives were invited at the workshop to express their in-
dividual opinion and not to act officially on behalf of
their organization; however, their commitment to cre-
ate awareness by dissemination and outreach of the
workshop deliverables at their local level is expected.
Clinicians and other professionals attending the work-
shop also agreed on the conclusions. They suggested
to promote these changes in their own environment
and implement them in their activities related to re-
search, for instance by including patients in Executive
or Safety boards for a trial, and education, e.g. by
having patient representatives take part in the dissem-
ination of standards of care.
Finally, it was hoped that such cultural change is also
supported by structural and legal requirements, in order
to make PPI included in the plans and realistically devel-
oped. Although based on the experience of the strong
neuromuscular community, these conclusions do not
apply only to this specific field; they fit rather well
with the considerations recently reported by other ex-
perts [58].
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